A Phase 3 interventional study of Sirolimus and AV Fistula Surgery in Complication of Renal Dialysis, End Stage Renal Disease and End Stage Kidney Disease, sponsored by Vascular Therapies, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-09.
Sponsored by Vascular Therapies, Inc. · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing sirolimus in Kidney Failure, Chronic — none open to participants now, none under way, none of them phase 3. Sirolimus · Kidney Failure, Chronic.
Among the 12 studies testing sirolimus in Kidney Failure, Chronic, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 3 in phase 3, and was the 11th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 12 studies testing sirolimus in Kidney Failure, Chronic is open now. The open studies under Kidney Failure, Chronic, anywhere →
Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 4 · Phase 4 2
First in 1999; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 269 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 80 across the 12 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 8 most frequent:
Vascular Therapies, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Vascular Therapies, Inc. has 2 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing sirolimus in Kidney Failure, Chronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate efficacy and safety outcomes following use of the Sirolimus-eluting Collagen Implant (SeCI) in subjects undergoing surgical creation of an AV fistula for vascular access (index procedure).
The objective of this study is to evaluate efficacy and safety outcomes following use of the Sirolimus-eluting Collagen Implant (SeCI) in subjects undergoing surgical creation of an AV fistula for vascular access (index procedure). Following successful creation of the AV fistula, the cohort randomized to the treatment group will receive the SeCI; the control group will not receive an implant. The primary hypothesis is that the proportion of subjects that meet requirements for fistula suitability for dialysis six months following the index procedure will be higher in the treatment group in comparison to the control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AV fistula surgery Single administration of sirolimus-eluting Collagen implant
Drug: Sirolimus · Procedure: AV Fistula Surgery · Device: Sirolimus-eluting Collagen Implant (SeCI)
AV fistula surgery
Procedure: AV Fistula Surgery
A single dose of sirolimus delivered locally
Also known as: Rapamycin
AV Fistula Surgery
SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
Also known as: Rapamycin
Fistula Suitability for Dialysis at 6 Months (FSD6)
For subjects who are on hemodialysis by day 150, suitability for dialysis will be determined by the ability to use the fistula for dialysis using 2-needles with a mean dialysis machine blood pump speed of ≥300 mL/min for two-thirds of the dialysis sessions during a 30 day suitability ascertainment period that begins 150 days after fistula creation. For subjects who are not on hemodialysis on day of enrollment and who do not initiate hemodialysis by day 150, suitability for dialysis will be determined by a vascular ultrasound performed at the 6 month follow up visit. Suitability for dialysis will be defined as a fistula with an access vein diameter (AVD) of ≥6 mm (internal diameter) and an access blood flow of ≥500 mL/min.
Time frame: 6 months
| Milestone | Sirogen | Control | Run-in |
|---|---|---|---|
| Started | 125 | 118 | 26 |
| Completed | 105 | 101 | 22 |
| Not completed | 20 | 17 | 4 |
| Withdrew: Withdrawal by subject | 9 | 7 | 2 |
| Withdrew: Lost to follow-up | 2 | 4 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 |
| Withdrew: Death | 8 | 4 | 2 |
For subjects who are on hemodialysis by day 150, suitability for dialysis will be determined by the ability to use the fistula for dialysis using 2-needles with a mean dialysis machine blood pump speed of ≥300 mL/min for two-thirds of the dialysis sessions during a 30 day suitability ascertainment period that begins 150 days after fistula creation. For subjects who are not on hemodialysis on day of enrollment and who do not initiate hemodialysis by day 150, suitability for dialysis will be determined by a vascular ultrasound performed at the 6 month follow up visit. Suitability for dialysis will be defined as a fistula with an access vein diameter (AVD) of ≥6 mm (internal diameter) and an access blood flow of ≥500 mL/min.
| Participants | Sirogen | Control | Run-in |
|---|---|---|---|
| Met FSD6 criteria | 74 | 76 | 21 |
| Did not meet FSD6 criteria | 43 | 35 | 5 |
| Indeterminant FSD6 | 8 | 7 | 0 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sirogen | 8/127 (6.3%) | 56/127 (44.1%) | 115/127 (90.6%) |
| Control | 4/116 (3.4%) | 55/116 (47.4%) | 101/116 (87.1%) |
| Run-in | 2/26 (7.7%) | 15/26 (57.7%) | 24/26 (92.3%) |
| Event | Sirogen | Control | Run-in |
|---|---|---|---|
| SepsisInfections and infestations | 1/127 | 1/116 | 3/26 |
| SyncopeNervous system disorders | 1/127 | 0/116 | 3/26 |
| End stage renal diseaseRenal and urinary disorders | 2/127 | 5/116 | 3/26 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/127 | 2/116 | 3/26 |
| Cardiac arrestCardiac disorders | 3/127 | 0/116 | 2/26 |
| Fluid overloadMetabolism and nutrition disorders | 3/127 | 5/116 | 2/26 |
| HyperkalaemiaMetabolism and nutrition disorders | 2/127 | 6/116 | 2/26 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/127 | 0/116 | 2/26 |
| Cardiac failure congestiveCardiac disorders | 7/127 | 3/116 | 0/26 |
| PneumoniaInfections and infestations | 6/127 | 6/116 | 0/26 |
| Event | Sirogen | Control | Run-in |
|---|---|---|---|
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 71/127 | 59/116 | 14/26 |
| Haemodialysis complicationInjury, poisoning and procedural complications | 41/127 | 35/116 | 6/26 |
| Arteriovenous fistula thrombosisInjury, poisoning and procedural complications | 17/127 | 18/116 | 6/26 |
| Arteriovenous fistula occlusionInjury, poisoning and procedural complications | 3/127 | 7/116 | 4/26 |
| ConstipationGastrointestinal disorders | 1/127 | 1/116 | 3/26 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/127 | 2/116 | 3/26 |
| Haemodialysis-induced symptomInjury, poisoning and procedural complications | 11/127 | 6/116 | 1/26 |
| Vision blurredEye disorders | 0/127 | 0/116 | 2/26 |
| Abdominal painGastrointestinal disorders | 3/127 | 1/116 | 2/26 |
| Fluid overloadMetabolism and nutrition disorders | 1/127 | 0/116 | 2/26 |
| Age, Categorical(Participants) | Sirogen | Control | Run-in | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 74 | 82 | 13 | 169 |
| >=65 years | 51 | 36 | 13 | 100 |
| Age, Continuous(years) | Sirogen | Control | Run-in | Total |
|---|---|---|---|---|
| Mean | 59.7 ± 14.9 | 57.7 ± 13.9 | 61.4 ± 17.3 | 59.0 ± 14.7 |
| Sex: Female, Male(Participants) | Sirogen | Control | Run-in | Total |
|---|---|---|---|---|
| Female | 28 | 23 | 6 | 57 |
| Male | 97 | 95 | 20 | 212 |
| Race (NIH/OMB)(Participants) | Sirogen | Control | Run-in | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 8 | 3 | 1 | 12 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Black or African American | 31 | 30 | 8 | 69 |
| White | 84 | 81 | 15 | 180 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 4 | 0 | 5 |
| Region of Enrollment(participants) | Sirogen | Control | Run-in | Total |
|---|---|---|---|---|
| United States | 125 | 118 | 26 | 269 |
| Kidney Disease Status at Enrollment(Participants) | Sirogen | Control | Run-in | Total |
|---|---|---|---|---|
| Chronic kidney disease | 33 | 36 | 1 | 70 |
| End stage renal disease | 92 | 82 | 25 | 199 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Nov 2015, a primary completion of Jun 2021 and a completion of Jun 2021. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2025, 4 years 4 months after primary completion. A results delay was requested in Jul 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus
Vascular Therapies, Inc.